“Immunotherapies take lead in liver cancer treatment"
By | translator Alice Kang
22.12.09 06:18:58
가나다라
0
Immunotherapy+ Immunotherapy combination introduced to the scene... reduced risk of toxicity and bleeding
Price of drug Imjudo key focus of attention... will limit patient options if its reimbursement is delayed
The lack of later-line therapy options remains the biggest barrier to the use of immuno-oncology drugs
“Immuno-oncology drugs have brought great advances in the treatment of unresectable advanced hepatocellular carcinoma. However, the unfortunate fact is that these are not well used in the field due to lack of later-line options.”
Professor Joong-Won Park, Division of Gastroenterology, National Cancer Center Korea, said so to Dailypharm at the ‘ESMO Asia Congress 2022’ that had been held in Singapore.
On the same day, Professor Park introduced the latest research trends in liver cancer treatment at a session held on ‘Patient care in hepatobiliary cancers: Emerging therapeutic approaches and remaining unmet needs.’
According to Professor Park, the treatment paradigm for un
(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)